Schrodinger

SDGR

Market cap $888M

Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger's performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “While the drug discovery AI la.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat on Tuesday, March 3, 2026 at 9:50 a.m. E.T. Leerink Global Healthcare Conference 2026: Fireside chat on Tuesday, March 10, 2026 at 1:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 17, 2026 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company's common stock to two newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,250 shares of the company's common stock to eight newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committe.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its comput.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. “In 2025, we witnessed the continued impact of scaling ‘physics+AI' to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We.

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger's widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead.

She and her team loaded up on two cryptocurrency-related companies. They also purchased an innovative healthcare tech stock.